Intensity Therapeutics, Inc.
- INTS
- NASDAQ
- Biotechnology
- Immuno-Oncology (Intratumoral)
- Solid Tumor Therapeutics
$3.29
Today −1.79%Quote Oct 19, 2026, 08:00 PM UTC
−19.95%over the last month
Max drawdown −21.9%From 1-month high −20.0%3 months −25.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
16
Market value
$10.7M
Quote Oct 19
Floor
$3.21
2.4% below price
Resistance
$3.50
6.3% above price
Price vs analyst targets
3 analysts
Lowest target
$7.00Highest target
$15.00
$7.00Highest target
$15.00
- Price $3.29
- Average target $11.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 234% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INTSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free